Loading...
Loading...
NEW YORK, NY · CIK 0001263508
Portfolio Value
$11.02B
Positions
135
New
10
Increased
14
Decreased
15
Sold Out
11
BAKER BROS. ADVISORS LP (NEW YORK, NY) reported a portfolio value of $11.02B across 135 positions in their Q3 2016 SEC 13F filing (period ending 2016-09-30). The top 10 positions account for 83.4% of the portfolio.
Top 30 holdings by portfolio weight. Block width = holding percentage. Green = new/increased, red = reduced, gray = unchanged.
| # | Stock | Value↓ | Weight | Change |
|---|---|---|---|---|
| 1 | SGENEURSeattle Genetics, Inc. | $2.38B | 21.61% | +2.0% |
| 2 | INCYIncyte Corporation | $2.22B | 20.11% | +0.0% |
| 3 | ABBVAbbVie Inc. | $904.64M | 8.21% | -0.2% |
| 4 | ACADACADIA Pharmaceuticals Inc. | $821.33M | 7.45% | +5.3% |
| 5 | ALXNAlexion Pharmaceuticals, Inc. | $801.82M | 7.28% | - |
| 6 | Incyte Corporation Notes 1.25% 11/15/2020 144A | $531.24M | 4.82% | - |
| 7 | Incyte Corporation Notes 0.375% 11/15/2018 144A | $491.34M | 4.46% | - |
| 8 | BMRNBioMarin Pharmaceutical Inc. | $444.70M | 4.04% | - |
| 9 | GHDXGenomic Health, Inc. | $398.24M | 3.61% | +0.7% |
| 10 | DBV Technologies S.A. | $200.16M | 1.82% | - |
| Stock | Value | Shares |
|---|---|---|
| CFRXEURContraFect Corporation | $10.03M | 4,045,876 |
| RCKT 5.75 08/01/21Inotek Pharmaceuticals Corporation Notes 5.75% 8/1/2021 | $6.71M | 5,000,000 |
| SNSSEURSunesis Pharmaceuticals, Inc. | $3.24M | 741,665 |
| MYOKEURMyoKardia, Inc. | $1.63M | 100,000 |
| CoLucid Pharmaceuticals, Inc. | $1.16M | 30,310 |
| FLGTFulgent Genetics, Inc. | $1.15M | 125,000 |
| APTOFAptose Biosciences Inc. | $909.00K | 404,211 |
| INFIQInfinity Pharmaceuticals, Inc. | $905.00K | 580,400 |
| MDGLMadrigal Pharmaceuticals, Inc. | $732.00K | 57,762 |
| ABEO1EURAbeona Therapeutics Inc. | $610.00K | 101,680 |
Get alerts when BAKER BROS. ADVISORS LP files new 13F holdings.